

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Insurance Code is amended by
5 changing Section 356u as follows:

6 (215 ILCS 5/356u)

7 Sec. 356u. Pap tests and prostate cancer screenings
8 ~~prostate-specific antigen tests.~~

9 (a) A group policy of accident and health insurance that
10 provides coverage for hospital or medical treatment or
11 services for illness on an expense-incurred basis and is
12 amended, delivered, issued, or renewed after January 1, 2024
13 ~~the effective date of this amendatory Act of 1997~~ shall
14 provide coverage, without imposing a deductible, coinsurance,
15 copayment, or any other cost-sharing requirement, for all of
16 the following:

17 (1) An annual cervical smear or Pap smear test for
18 female insureds.

19 (2) An annual prostate cancer screening ~~digital rectal~~
20 ~~examination and a prostate-specific antigen test,~~ for male
21 insureds upon the recommendation of a physician licensed
22 to practice medicine in all its branches for:

23 (A) asymptomatic men age 50 and over;

1 (B) African-American men age 40 and over; and

2 (C) men age 40 and over with a family history of
3 prostate cancer.

4 (3) Surveillance tests for ovarian cancer for female
5 insureds who are at risk for ovarian cancer.

6 (b) This Section shall not apply to agreements, contracts,
7 or policies that provide coverage for a specified disease or
8 other limited benefit coverage.

9 (c) This Section does not apply to coverage of prostate
10 cancer screenings to the extent such coverage would disqualify
11 a high-deductible health plan from eligibility for a health
12 savings account pursuant to Section 223 of the Internal
13 Revenue Code.

14 (d) ~~(e)~~ For the purposes of this Section:

15 "At risk for ovarian cancer" means:

16 (1) having a family history (i) with one or more
17 first-degree relatives with ovarian cancer, (ii) of
18 clusters of women relatives with breast cancer, or (iii)
19 of nonpolyposis colorectal cancer; or

20 (2) testing positive for BRCA1 or BRCA2 mutations.

21 "Prostate cancer screening" means medically viable methods
22 for the detection and diagnosis of prostate cancer, including
23 a digital rectal exam and the prostate-specific antigen test
24 and associated laboratory work. "Prostate cancer screening"
25 includes medically necessary subsequent follow-up testing as
26 directed by a health care provider, including, but not limited

1 to:

2 (1) urinary analysis;

3 (2) serum biomarkers; and

4 (3) medical imaging, including, but not limited to,
5 magnetic resonance imaging.

6 "Surveillance tests for ovarian cancer" means annual
7 screening using (i) CA-125 serum tumor marker testing, (ii)
8 transvaginal ultrasound, (iii) pelvic examination.

9 (Source: P.A. 94-122, eff. 1-1-06.)